TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1382291

Group type: EXPERIMENTAL
Intervention: Erythemagenic doses of UVB prior to sensitization with DNCB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suberythemagenic UV exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythemagenic doses of UVB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Localized moderate sunburn
Number of subjects: 0
Study: 29907082

Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (Div group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.5 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD0.5 group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1.0 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD1.0 group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2.0 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD2.0 group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ropivacaine (R group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (C group)
Number of subjects: 120
Study: 27804273

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (duration: 18 months)
Number of subjects: 52
Study: 23257166

Group type: EXPERIMENTAL
Intervention: FATaintPHAT intervention
Number of subjects: 883
Study: 22317271

Group type: EXPERIMENTAL
Intervention: Virtual reality based therapy (VRBT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 20013927

Group type: EXPERIMENTAL
Intervention: 1.2 g co-amoxiclav (prophylactic dose)
Number of subjects: 443

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (control)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 443
Study: 18226045

Group type: EXPERIMENTAL
Intervention: Raloxifene treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study: 16755158

Group type: EXPERIMENTAL
Intervention: Vitamin E-coated dialyzer
Number of subjects: 16
Study: 12960599

Group type: EXPERIMENTAL
Intervention: Non-corrected (NC) images
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Attenuation- and scatter-corrected (AC-SC) images
Number of subjects: 607

Group type: COMPARATOR
Intervention: Combined evaluation of NC and AC-SC images
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Attenuation and scatter correction
Number of subjects: 607
Study: 10730687

Group type: EXPERIMENTAL
Intervention: Argatroban 125-microg/kg bolus followed by 4-hour continuous infusion of 2.5 microg/kg/minute (Study 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Argatroban 4-hour infusion of 2.5 microg/kg/minute (Study 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Argatroban 5-microg/kg/minute continuous infusion over 4 hours (Study 3)
Number of subjects: 40
Study: 8703452

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 16
Study: 1572183

Group type: EXPERIMENTAL
Intervention: iv ranitidine to increase gastric pH greater than 4
Number of subjects: 34

Group type: COMPARATOR
Intervention: No prophylaxis for upper gastrointestinal bleeding (control group)
Number of subjects: 34
Study: 3966507

Group type: EXPERIMENTAL
Intervention: Manual manipulation of the fetus prior to the nonstress test
Number of subjects: 790

Group type: COMPARATOR
Intervention: No manual manipulation of the fetus (control group)
Number of subjects: 790
Study: 31201218

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days, titrated to a maximum of 15 g over 4 weeks.
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 196
Study: 29717473

Group type: EXPERIMENTAL
Intervention: Inhalable doxorubicin (25 mg/m2)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cisplatin (10 mg/m2)
Number of subjects: 240
Study: 26786584

Group type: EXPERIMENTAL
Intervention: Brisk walking program (78 sessions over 6 months, 3 sets of 60 min of exercise per week)
Number of subjects: 121
Study: 24960516

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg/day)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 22935482

Group type: EXPERIMENTAL
Intervention: Albuminuria at 1-2 μg/min
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 1208

Group type: COMPARATOR
Intervention: ACEI therapy
Number of subjects: 1208
Study: 19962275

Group type: EXPERIMENTAL
Intervention: Right ventricular septal (RVS) pacing
Number of subjects: 46

Group type: COMPARATOR
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 46
Study: 18496484

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (AmF-SnF(2))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorhexidine 0.12% (CHX) followed by AmF-SnF(2)
Number of subjects: 30
Study: 15803299

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metaraminol
Number of subjects: 10
Study: 12440139

Group type: EXPERIMENTAL
Intervention: 300 mg of INH per day for 6 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Follow-up by chest X-ray
Number of subjects: 29
Study: 10367995

Group type: EXPERIMENTAL
Intervention: Tower of Hanoi test
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: WCST
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Discriminant analysis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Common underlying factor
Number of subjects: 28
Study: 8634219

Group type: EXPERIMENTAL
Intervention: Tamils of the plains, Madras City (N = 142)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Kota tribe (N = 48)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Family material (N = 54) including 37 offspring
Number of subjects: 190
Study: 2325924

Group type: EXPERIMENTAL
Intervention: Group reminiscence counseling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 7028200

Group type: EXPERIMENTAL
Intervention: Naloxone (0.3 mg/Kg b.wt.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29843500

Group type: EXPERIMENTAL
Intervention: PCD+PD (percutaneous catheter drainage combined with peritoneal dialysis)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Convention group (conventional method)
Number of subjects: 64
Study: 28556519

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 19

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Belatacept (after 3 months of tacrolimus)
Number of subjects: 19
Study: 25527488

Group type: EXPERIMENTAL
Intervention: 30 hours of task-specific upper-limb training in the first month poststroke
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 23
Study: 23816960

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg per day
Number of subjects: 345

Group type: COMPARATOR
Intervention: Cisplatin plus pemetrexed chemotherapy
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Afatinib (specifically for exon 19 deletions and L858R mutations)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 345
Study: 21184877

Group type: EXPERIMENTAL
Intervention: Orientation device
Number of subjects: 4

Group type: COMPARATOR
Intervention: No orientation device
Number of subjects: 4
Study: 19430098

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment-experienced patients
Number of subjects: 348

Group type: COMPARATOR
Intervention: Antiretroviral treatment-naive patients
Number of subjects: 348

Group type: COMPARATOR
Intervention: Comparison of polymerase domain between treatment-experienced and treatment-naive patients
Number of subjects: 348

Group type: COMPARATOR
Intervention: Comparison of thumb-connection domain between treatment-experienced and treatment-naive patients
Number of subjects: 348

Group type: COMPARATOR
Intervention: Comparison of RNase H domain between treatment-experienced and treatment-naive patients
Number of subjects: 348
Study: 17679017

Group type: EXPERIMENTAL
Intervention: Visual inspection with 4% acetic acid (VIA) screening
Number of subjects: 49311

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 49311
Study: 16352489

Group type: EXPERIMENTAL
Intervention: Leukocyte depleting filter
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no leukocyte filter)
Number of subjects: 20
Study: 11867826

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (1000 microg daily) for 3 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 10223257

Group type: EXPERIMENTAL
Intervention: Boys with depression
Number of subjects: 38

Group type: COMPARATOR
Intervention: Boys without depression
Number of subjects: 38
Study: 7849886

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (aminophylline)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 42
Study: 2083923

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 800 mg/day i.v.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7211263

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg metoprolol tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% metoprolol eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% metoprolol eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3% metoprolol eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% metoprolol eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% metoprolol eye drops administered twice daily for 6 weeks
Number of subjects: 0
Study: 31573939

Group type: EXPERIMENTAL
Intervention: ARMADILLO intervention (arm 1)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Once-a-week contact SMS text message (arm 2)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Usual care (arm 3)
Number of subjects: 660
Study: 27665941

Group type: EXPERIMENTAL
Intervention: Mitii™ (web-based program) for 20 weeks; n=51
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waitlist control; n=50
Number of subjects: 102
Study: 26279062

Group type: EXPERIMENTAL
Intervention: Microneedle array application
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-prick lancet piercing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adhesive-tape stripping
Number of subjects: 20
Study: 22435646

Group type: EXPERIMENTAL
Intervention: Condom promotion program (45-60 minutes, one-on-one session)
Number of subjects: 136

Group type: COMPARATOR
Intervention: General health program (attention-matched comparison condition)
Number of subjects: 136
Study: 21980653

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCABG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 60
Study: 19477358

Group type: EXPERIMENTAL
Intervention: Intravenous ANP (0.025 microg/kg/min for 3 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 17320191

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for depression
Number of subjects: 151
Study: 14996517

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 10 days
Number of subjects: 493

Group type: COMPARATOR
Intervention: High-dose clarithromycin 500 mg twice daily for 10 days
Number of subjects: 493
Study: 15014819

Group type: EXPERIMENTAL
Intervention: Fentanyl 4 microg/kg and midazolam 0.04 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl 4 microg/kg
Number of subjects: 40
Study: 9196677

Group type: EXPERIMENTAL
Intervention: Compliance enhancement strategy (extra education using video, booklets, posters, checklist, health care contract)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard level of contact lens instruction
Number of subjects: 80
Study: 1947787

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6228473

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine in combination with Hepatitis B immunoglobulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30894130

Group type: EXPERIMENTAL
Intervention: Pilot 2 methods (pre-notification, shorter questionnaire, personable materials, additional reminder, QR codes)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Pilot 2 methods (QR codes)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Pilot 1 methods (baseline)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Pilot 2 methods (additional reminder)
Number of subjects: 3000
Study: 29912819

Group type: EXPERIMENTAL
Intervention: Balloon dilation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (continued medical therapy)
Number of subjects: 60
Study: 27938375

Group type: EXPERIMENTAL
Intervention: Economic support (cash transfers and payment of school fees)
Number of subjects: 4900

Group type: EXPERIMENTAL
Intervention: Economic support combined with a community intervention
Number of subjects: 4900
Study: 25999242

Group type: EXPERIMENTAL
Intervention: Asymptomatic HRV infections
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Symptomatic HRV infections
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 502
Study: 22715981

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 138)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (n = 152)
Number of subjects: 290
Study: 20302673

Group type: EXPERIMENTAL
Intervention: Autologous iliac crest graft (AICG)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: PEEK cage
Number of subjects: 258

Group type: COMPARATOR
Intervention: Both AICG and PEEK cage
Number of subjects: 258
Study: 18468575

Group type: EXPERIMENTAL
Intervention: History of unplanned pregnancy
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Young age and low educational status
Number of subjects: 542
Study: 16330766

Group type: EXPERIMENTAL
Intervention: Gabapentin (1,800 mg per os, single administration)
Number of subjects: 0
Study: 12059873

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone pulse therapy (group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Oral prednisone (group B)
Number of subjects: 33
Study: 10472215

Group type: EXPERIMENTAL
Intervention: Fibreoptic reflectance oximetry catheter
Number of subjects: 33

Group type: COMPARATOR
Intervention: Bench oximeter
Number of subjects: 33
Study: 8758124

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate 200 micrograms twice daily for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1736604

Group type: EXPERIMENTAL
Intervention: Dipyridamole 75 mg every 8 hours for 2 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 15
Study: 328328

Group type: COMPARATOR
Intervention: Penbutolol 25 mg and 50 mg (in 10 patients); 25 mg, 50 mg, and 100 mg (in 2 patients)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30762404

Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling adjunct (LP1)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling adjunct (LP2)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling adjunct (LP3)
Number of subjects: 343
Study: 29083433

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (150kcal, 20g whey protein, 800 IU vitamin D)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo (30kcal, non-nutritive)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 25527336

Group type: EXPERIMENTAL
Intervention: EHR-recorded data on Hispanic ethnicity
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: EHR-recorded data on African American race
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: EHR-recorded language preference for Spanish
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Self-reported identification with other racial or ethnic groups
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: EHR-documented Spanish speakers
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Individuals recorded as English-speaking in EHR
Number of subjects: 569
Study: 23001082

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (1 g ampicillin-sulbactam intravenously at anesthesia)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 369
Study: 22108482

Group type: EXPERIMENTAL
Intervention: mf Odontovis Calcium® (calcium salts, Vitamin D, and physiological modulators with antioxidant activity)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (best treatment without mf Odontovis Calcium®)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: mf Odontovis Calcium®
Number of subjects: 79
Study: 19805640

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet supplemented with nuts
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet supplemented with virgin olive oil
Number of subjects: 36
Study: 22994061

Group type: EXPERIMENTAL
Intervention: pVIS + pIR radiation applied to the lumbar‐sacral region from days 1 to 7 after surgery
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard course of postoperative rehabilitation (control)
Number of subjects: 19
Study: 16167938

Group type: EXPERIMENTAL
Intervention: Plasma volume expansion and a diastolic BP target of 85-95 mmHg
Number of subjects: 216

Group type: COMPARATOR
Intervention: Intravenous fluid restriction and BP target of 95-105 mmHg
Number of subjects: 216
Study: 14572325

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension administered with an Adaptive Aerosol Delivery (AAD) system
Number of subjects: 125
Study: 14590596

Group type: EXPERIMENTAL
Intervention: Sad mood induction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Anxious mood induction
Number of subjects: 80

Group type: COMPARATOR
Intervention: Positive mood induction
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paced Auditory Serial Addition Task (PASAT)
Number of subjects: 80
Study: 2694097

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental) intravenous treatment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental) oral treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (control) intravenous treatment
Number of subjects: 39
Study: 365125

Group type: EXPERIMENTAL
Intervention: Temperature biofeedback with autogenic training and regular home practice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Progressive relaxation with regular home practice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Follow-up data for both treated groups (biofeedback and relaxation)
Number of subjects: 30
Study: 12799121

Group type: EXPERIMENTAL
Intervention: Experimental carbonated blackcurrant drink
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional carbonated orange drink
Number of subjects: 15

Group type: COMPARATOR
Intervention: Water
Number of subjects: 15
Study: 29439002

Group type: EXPERIMENTAL
Intervention: CTLB antenatal education programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27160473

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Anterolateral thoracotomy
Number of subjects: 206
Study: 25156178

Group type: EXPERIMENTAL
Intervention: V3P-brace
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: VER-brace
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ACL-brace
Number of subjects: 24
Study: 22413453

Group type: EXPERIMENTAL
Intervention: US-guided short-axis group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: US-guided long-axis group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Blind palpation technique group
Number of subjects: 36
Study: 20431975

Group type: EXPERIMENTAL
Intervention: physician advice
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: assistance
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: counseling
Number of subjects: 878
Study: 18317392

Group type: EXPERIMENTAL
Intervention: 1 mg/kg prednisone for 5 days, followed by gradually reduced doses for an additional 15 days, and vestibular sedatives for symptomatic relief during the first 5 days.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo and similar vestibular sedatives.
Number of subjects: 30
Study: 16135860

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 347

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 347
Study: 11995347

Group type: EXPERIMENTAL
Intervention: BIS monitoring (n = 20)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 46
Study: 10102604

Group type: EXPERIMENTAL
Intervention: Full mouth series of radiographs
Number of subjects: 65

Group type: COMPARATOR
Intervention: Panoramic radiographs
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both modalities (panoramic and full mouth series)
Number of subjects: 65
Study: 8649929

Group type: EXPERIMENTAL
Intervention: DSSS system for detecting HCMV DNA
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Agarose gel electrophoresis (ethidium bromide staining)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Detection of HCMV DNA in urine samples
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Detection of specific anti-HCMV antibodies
Number of subjects: 31